Research

Mixed

Supplementation with L-carnitine is not recommended for CPTII deficiency patients because it does not significantly improve muscle carnitine content, may increase cardiovascular risk via TMAO production, and acyl-carnitine accumulation cannot be fully processed due to the enzyme defect.

Do not take L-carnitine supplements. They do not fix the underlying enzyme problem and may increase your risk of heart disease by creating harmful byproducts (TMAO). Stick to the recommended diet and exercise plan.

ModerateRefutesMEDIUM confidence
a chronic supplementation of carnitine should be discouraged in these patients... carnitine can be partly degraded to trimethylamine-N-oxide (TMAO), which is considered a novel risk factor for cardiovascular diseases... in muscle CPTII deficiency acyl-carnitine is only partially transported across the inner mitochondrial membrane and the conversion of acylcarnitine into acyl-CoA is anyway insufficient to justify carnitine supplementation
Massimo Negro et al. · Frontiers in Physiology · 2021

Why this rating

Based on biochemical reasoning and general population studies on TMAO; limited direct clinical trial data in CPTII patients.

Source

Exercise, Nutrition, and Supplements in the Muscle Carnitine Palmitoyl-Transferase II Deficiency: New Theoretical Bases for Potential Applications

Massimo Negro et al. · Frontiers in Physiology · 2021

DOI 10.3389/fphys.2021.704290

narrative_reviewCited 13×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →